Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, and the question for the next twelve months is whether the company can convert the FDA approval of REVTORPYK (gedatolisib) in July 2026, the NCCN Category 1 recommendation, the planned sNDA submission in Q3 2026, and the $575 million convertible note offering into a successful commercial launch. The Q2 2026 print was the cleanest test yet of that thesis, and the cleanest signal is that on July 14, 2026, the U.S. FDA approved REVTORPYK for the treatment of patients with HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The combination of the FDA approval of REVTORPYK on July 14, 2026, the on-track commercial launch late in the third quarter of 2026, the NCCN Clinical Practice Guidelines recommendation of REVTORPYK in combination with fulvestrant, with or without palbociclib, as a preferred Category 1 option for second-line therapy in HR+/HER2- advanced breast cancer, the Phase 3 PIK3CA mutant cohort of the VIKTORIA-1 trial achieving its primary endpoint by doubling the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant, the planned supplemental New Drug Application (sNDA) submission in the third quarter of 2026, the Phase 3 VIKTORIA-2 trial expansion to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer, the completed $575.0 million convertible note offering with net proceeds of $557.2 million, the build-out of the commercialization infrastructure for REVTORPYK completion, the commencement of commercial launch activities for REVTORPYK immediately after approval, the shipments of REVTORPYK expected to begin late in the third quarter of 2026, the Expanded Access Program (EAP) opening to participating physicians on behalf of eligible patients, the distribution of gedatolisib to those physicians, the management to host webcast and conference call on August 13, 2026, the tens of thousands of patients affected each year by HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer, the significant unmet need, the treatment-naive patient positioning in VIKTORIA-2 expansion, the nearly all patients in the first- and second-line setting availability, the FDA approval in 2nd line PIK3CA Wild-Type setting, the FDA approval in 2nd line PIK3CA Mutant-Type setting, the pan-PI3K, mTORC1/2 inhibitor mechanism of action, the VIKTORIA-1 study, the VIKTORIA-2 study, and the multi-indication potential is the cleanest single read on what the REVTORPYK-launch pivot is producing. The strategic tension is the late-Q3 2026 commercial launch against the PIK3CA mutant sNDA submission timing, and the forward question is whether the company can convert the FDA approval and the NCCN Category 1 recommendation into a successful commercial launch and the planned sNDA submission into a PIK3CA mutant approval.